Competitive Technologies announced today that patent number 6,808,561 has been issued by the US Patent Office for Dr. Brian R. Genge's nanotechnology bone biomaterial developed at the Universi
Patent litigation remains the most commonly used generic defense strategy among pharmaceutical companies. 71% of drug companies have used legal battles to defend their patents in the past three years, according to research from pharmaceutical business
Morphotek announced today the issuance of United States Patent 6,808,894 covering the generation of genetically enhanced antibody producer cell lines. The issued patent covers the use of the
Hydroderm announced today that after years of clinical research, Hydroderm's exclusive Collagen Infusion Delivery System was granted a U.S. patent. The system delivers whole molecules of mar
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Dir
Morphotek announced today the issuance of United States Patent 6,825,038 covering the regulation of mismatch repair (MMR), a powerful process for generating functional diversity in mammalian cells,
Biolase Technology today announced that it has been granted a new U.S. patent protecting key areas related to its laser pulse technology. U.S. Patent No. 6,821,272, granted by the U.S. Patent
Tercica announced today the filing of a suit for patent infringement in the High Court of Justice (Chancery Division Patents Court) in the United Kingdom against Insmed Incorporated of Glen Allen, Vir
Genaissance Pharmaceuticals received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming methods for identifying correlations between the safety and effi
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applic
This first patent grant in China is important as China has the highest incidence of primary liver cancer in the world with 345,844 cases in 2002 and is a logical target market for BrachySil. The potential lower cost of the Chinese registration pathway and the vast need of BrachySil like products make China an important commercial target.
pSivida is currently in exploratory discussions with commercialisation partners for the Chinese market for its lead product BrachySil and is investigating the optimum regulatory process to launch this product in China. It is expected that pSivida would enter into a supply agreement with a local distributor responsible for obtaining regulatory approval, sales and marketing. pSivida Managing Director Gavin Rezos said, "China is a massive market offering pSivida significant opportunities for commercial expansion. In recent years China has opened its 'commercial doors' to many western products, healthcare being no exception. Although our main short term interest is to launch BrachySil in China, we believe other products in the drug delivery arena will also be good candidates for this rapidly growing market." Chinese Patent Number ZL 99807447.0 provides protection for silicon implants comprising tissue compatible biodegradable silicon for drug delivery. This invention was based on the demonstration in model systems, that long term BioSilicon implants lack toxicology and degrade in the body in a controllable manner. It also claims the loading of BioSilicon implants of varying porosity and structure with different drugs. The pSivida Intellectual Property portfolio consists of 26 patent families, 29 granted patents and over 80 patent applications.
Products protected by patents and patent applications owned by pSivida include materials comprising bioactive, resorbable and biocompatible silicon that are of value in the fabrication of new generations of intelligent drug delivery devices, orthopaedic implants and intelligent diagnostic tools.
http://www.psivida.com/